CARTITUDE 1 Update - Cilta-Cel | Mark Wildgust, PhD | ASH 2021

(3:)

Ide-cel versus cilta-cel in multiple myeloma: a collaborative decision between patient and doctor

(1:33)

Cilta-cel versus SoC in functionally high-risk myeloma with one prior therapy

(2:21)

Cilta-cel in earlier lines of therapy for R/R multiple myeloma

(1:47)

Long-Term Efficacy and Safety of Cilta-Cel in Patients With Relapsed/Refractory Multiple Myeloma

(1:35)

CARTITUDE-4 Cilta-cel Efficacy in Myeloma | Binod Dhakal, MD | ASCO 2023

(6:43)

OS with Cilta-cel vs SOC in Lenalidomide Refractory MM | María-Victoria Mateos, MD, PhD | IMS 2024

(4:)

Cilta-cel versus conventional treatment in patients with relapse/refractory multiple myeloma

(4:10)

Latest Results from the CARTITUDE-2 Study Testing Cilta-cel in Multiple Myeloma Patients

(5:34)

Hitting the BCMA Target in Multiple Myeloma

(55:48)

CARTITUDE-2: evaluating CAR T therapy Cilta-Cel in multiple myeloma patients who had early relapse

(5:3)

MRD Results from Cartitude-4 (Cilta-Cel vs SOC) in RRMM | Rakesh Popat | #ASH24

(3:6)

Cilta-cel in R/R myeloma: preliminary results from CARTITUDE-1

(5:44)

CARTITUDE-1 final results: PFS of cilta-cel in patients with heavily pre-treated R/R myeloma

(1:38)

Neurologic adverse effects in pts with MM treated with cilta-cel in CARTITUDE-2

(9:34)

CARTITUDE-4: Cilta-cel vs standard of care PVd or DPd in lenalidomide-refractory multiple myeloma

(11:43)

MRD negativity in the CARTITUDE-4 trial of cilta-cel vs SoC in R/R multiple myeloma

(2:11)

Real-World CAR-T Outcomes, Use of Ide-cel, Cilta-cel for Myeloma

(7:55)